清痰通络方治疗慢性阻塞性肺疾病急性加重期痰瘀阻肺证临床疗效观察OA

Objective:To evaluate the clinical efficacy of Qingtan Tongluo Formula combined with conventional Western medicine therapy for treating patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)presenting with the syndrome of phlegm stasis obstructing the lung.Additionally,to assess its modulatory effects on in-flammation and coagulation parameters.Methods:80 AECOPD patients diagnosed with the phlegm stasis obstructing the lung syndrome were enrolled from Jinjiang Hospital between July 2024 and July 2025.Participants were equally al-located into either a Chinese medicine(CM)group or a control group using a random number table.The control group received standardized Western medical treatment alone.The CM group received identical Western medical treatment and adjunctive therapy with Qingtan Tongluo Formula for 7 consecutive days.Comparisons were made between the two groups regarding:(1)Clinical efficacy rate;(2)Traditional Chinese medicine(TCM)syndrome scores(specifically for wheezing and fever);(3)Complete blood count parameters and derived inflammatory indices:Neutrophil(NEU),Lymphocyte(LYM),Monocyte(MONO)counts,Neutrophil-to-Lymphocyte Ratio(NLR),and Systemic Inflamma-tion Response Index(SIRI);(4)Serum inflammatory markers:C-reactive Protein(CRP)and Procalcitonin(PCT);and(5)Coagulation function markers:Fibrinogen(FIB)and D-Dimer(D-D).Results:The effective treatment rate of the TCM group was 95%,which was significantly higher than that of the control group(80%)(P<0.05;relative risk[RR]=1.19,95%confidence interval[CI]=[1.03,1.37]).After treatment,the TCM group demonstrated superior improvements in wheezing(P=0.001,95%CI=[0.69,0.89]),fever(P=0.016,95%CI=[0.81,0.98]),and to-tal TCM syndrome score(P=0.002,95%CI=[0.71,0.95])compared to the control group(all P<0.05).Regard-ing immune-related indices,the TCM group showed a more significant increase in lymphocyte count(LYM)(P=0.039,95%CI=[1.01,1.25]),and greater reductions in neutrophil-to-lymphocyte ratio(NLR)(P=0.021,95%CI=[0.73,0.97])and systemic inflammation response index(SIRI)(P=0.036,95%CI=[0.74,0.99])than the con-trol group(all P<0.05).Additionally,the TCM group exhibited more pronounced improvements in inflammatory markers,including C-reactive protein(CRP)(P=0.013,95%CI=[0.85,1.11]),procalcitonin(PCT)(P=0.005,95%CI=[0.71,0.95]),and coagulation function indicator fibrinogen(FIB)(P=0.004,95%CI=[0.72,0.96]),when compared to the control group(all P<0.05).Conclusion:Qingtan Tongluo Formula combined with conventional Western medicine demonstrates favorable clinical efficacy in treating AECOPD patients with the phlegm-blood stasis obstruc-ting the lung syndrome.This integrated approach significantly alleviates clinical symptoms,mitigates the systemic inflammato-ry response,and improves coagulation function.It is,therefore,worthy of clinical promotion and broader application.